Will FedEx’s Spinoff Boost Its Stock Price?
In a pre-holiday surprise announcement, management at FedEx (NYSE:FDX) released…
Sell
34
KYMR Quote, Financials, Valuation and Earnings
Last price:
$39.28
Seasonality move
:
-5.72%
Day range:
$39.78 - $42.67
52-week range:
$22.35 - $53.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
31.89x
P/B ratio:
2.91x
Volume:
429.2K
Avg. volume:
489.2K
1-year change:
54.09%
Market cap:
$2.6B
Revenue:
$78.6M
EPS (TTM):
-$2.34
Analysts' Opinion
-
Consensus RatingKymera Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $58.74, Kymera Therapeutics has an estimated upside of 46.44% from its current price of $40.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $41.00 representing -2.22% downside risk from its current price of $40.11.
Fair Value
-
According to the consensus of 17 analysts, Kymera Therapeutics has 46.44% upside to fair value with a price target of $58.74 per share.
KYMR vs. S&P 500
-
Over the past 5 trading days, Kymera Therapeutics has overperformed the S&P 500 by 1.79% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Kymera Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kymera Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Kymera Therapeutics reported revenues of $3.7M.
Earnings Growth
-
Kymera Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Kymera Therapeutics reported earnings per share of -$0.82.
Enterprise value:
2B
EV / Invested capital:
2.29x
Price / LTM sales:
31.89x
EV / EBIT:
--
EV / Revenue:
23.39x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-13.82x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-21.71%
Net Income Margin (TTM):
-191.26%
Return On Equity:
-27.19%
Return On Invested Capital:
-27.19%
Operating Margin:
-1927.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $46M | $46.8M | $87.6M | $4.7M | $3.7M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$156.6M | -$184.8M | -$195.3M | -$57.5M | -$72.1M | |
| EBITDA | -$150.8M | -$163.8M | -$161M | -$51.9M | -$60.4M | |
| Diluted EPS | -$2.94 | -$2.87 | -$2.34 | -$0.90 | -$0.82 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $297.4M | $543.7M | $494M | $375.7M | $568.7M | |
| Total Assets | $507.4M | $642.5M | $638.5M | $552.4M | $1B | |
| Current Liabilities | $107.3M | $94.5M | $91.1M | $63.2M | $66.5M | |
| Total Liabilities | $212.7M | $159.3M | $125.6M | $156.8M | $141.9M | |
| Total Equity | $294.7M | $483.1M | $512.9M | $395.5M | $892.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$151.9M | -$150.4M | -$124.7M | -$31.6M | -$50.2M | |
| Cash From Investing | $2.2M | $71.3M | -$453.7M | $60.5M | -$157.7M | |
| Cash From Financing | $153.1M | $4.2M | $608M | -$206K | $250.9M | |
| Free Cash Flow | -$154.9M | -$173.6M | -$148.2M | -$39.7M | -$50M | |
KYMR
Sector
Market Cap
$2.6B
$45.9M
Price % of 52-Week High
75.3%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
-19.47%
-0.6%
1-Year Price Total Return
54.09%
-32.15%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$40.60
200-day SMA
Sell
Level
$41.27
Bollinger Bands (100)
Sell
Level
42.77 - 48.77
Chaikin Money Flow
Buy
Level
12.9M
20-day SMA
Sell
Level
$43.21
Relative Strength Index (RSI14)
Sell
Level
40.01
ADX Line
Buy
Level
9.02
Williams %R
Neutral
Level
-70.7364
50-day SMA
Sell
Level
$45.58
MACD (12, 26)
Sell
Level
-1.50
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
7.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.3677)
Sell
CA Score
(Annual)
Level (-0.3844)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (1.0686)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Stock Forecast FAQ
In the current month, KYMR has received 13 Buy ratings 4 Hold ratings, and 0 Sell ratings. The KYMR average analyst price target in the past 3 months is $58.74.
-
Where Will Kymera Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kymera Therapeutics share price will rise to $58.74 per share over the next 12 months.
-
What Do Analysts Say About Kymera Therapeutics?
Analysts are divided on their view about Kymera Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kymera Therapeutics is a Sell and believe this share price will drop from its current level to $41.00.
-
What Is Kymera Therapeutics's Price Target?
The price target for Kymera Therapeutics over the next 1-year time period is forecast to be $58.74 according to 17 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is KYMR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kymera Therapeutics is a Buy. 13 of 17 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KYMR?
You can purchase shares of Kymera Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kymera Therapeutics shares.
-
What Is The Kymera Therapeutics Share Price Today?
Kymera Therapeutics was last trading at $39.28 per share. This represents the most recent stock quote for Kymera Therapeutics. Yesterday, Kymera Therapeutics closed at $40.11 per share.
-
How To Buy Kymera Therapeutics Stock Online?
In order to purchase Kymera Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 30
Lemonade [LMND] is down 2.82% over the past day.
Buy
63
SMLR alert for Dec 30
Semler Scientific [SMLR] is down 11.17% over the past day.
Sell
39
DOGZ alert for Dec 30
Dogness (International) [DOGZ] is up 3.61% over the past day.
